Product Images Gabapentin

NDC number 70934-933-90 reveals that the product is Gabapentin tablets, USP. No further information is available as the rest of the text appears to be an error or incomplete.*

This text seems to provide some sort of medical calculation involving a person's gender and serum creatinine levels. The formula involves multiplying the serum creatinine level in mg/dL by 72 and then multiplying the result by either 0.85 (for female patients) or 1 (for male patients), possibly to calculate the estimated glomerular filtration rate (eGFR). The meaning of the first line "140 - ight" is not clear and seems to be a typographical error.*

The text states mean pain score and shows a four-week dose titration period followed by a four-week fixed dose period with a placebo and Gabapentin dose of 3600 mg/day. It also includes a baseline score of one.*

This appears to be a table or chart with columns indicating a "Mean Pain Score" and different treatment options such as a placebo, 1800 mg/day of Gabapentin, and 2400 mg/day of Gabapentin. There are also two periods indicated - a four-week fixed dose period and a week of baseline. Without more information or context, it is difficult to provide further useful description.*

The text is describing a figure showing the proportion of responders with a reduction in pain score in controlled PHN studies. The figure includes percentages ranging from 0% to 100%, with specific values for different studies such as GBP 3600 and PBO. There is a note of statistical significance indicated by "#p<00l< 0,001".*